(S)-2-{(R)-2-[((3S,6S)-5,11-Dioxo-17-oxa-4,10-diaza-tricyclo[16.2.2.06,10]docosa-1(21),18(22),19-triene-3-carbonyl)-amino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid

ID: ALA1790701

PubChem CID: 56668770

Max Phase: Preclinical

Molecular Formula: C32H48N4O7

Molecular Weight: 600.76

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC[C@@H](C)[C@@H](NC(=O)[C@@H]1Cc2ccc(cc2)OCCCCCC(=O)N2CCC[C@H]2C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)O

Standard InChI: InChI=1S/C32H48N4O7/c1-5-21(4)28(31(40)34-25(32(41)42)18-20(2)3)35-29(38)24-19-22-12-14-23(15-13-22)43-17-8-6-7-11-27(37)36-16-9-10-26(36)30(39)33-24/h12-15,20-21,24-26,28H,5-11,16-19H2,1-4H3,(H,33,39)(H,34,40)(H,35,38)(H,41,42)/t21-,24+,25+,26+,28-/m1/s1

Standard InChI Key: WLEBKPCOWKLDCS-AWTHHPGASA-N

Molfile:

     RDKit          2D

 44 46  0  0  1  0  0  0  0  0999 V2000
   -0.2250   -0.8417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1417   -0.9125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8125   -0.5292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1375   -0.9125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042   -0.9125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1375   -0.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4750   -0.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4750   -0.9125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8000   -0.5292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2083   -1.7917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4750   -0.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4667   -0.9125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1375   -0.5292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1417   -1.6792    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.1375   -1.6792    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1375    0.2333    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3000   -1.7667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0250   -2.2917    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.1375    0.2333    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4667   -1.6792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9125   -4.6167    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5125   -3.9125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7125   -2.4792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4750    0.2333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7375   -0.2750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8000   -0.9125    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9250   -3.2000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6875   -3.8917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5250   -2.4917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2875   -3.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4042    0.2333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6250   -2.2542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3583    0.3875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1375   -2.0667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4750   -5.2000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042    0.6208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1375    0.6208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1375   -2.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8000   -1.6792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6292   -3.2125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042    1.3958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4792   -4.6167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4667   -3.6750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3165    0.0111    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  7  2  1  0
  3  2  1  0
  4 11  1  0
  5  6  1  0
  8  6  1  6
  7  1  1  0
  8  3  1  0
  9  4  1  0
 10  1  1  0
 11  5  1  6
 12  9  1  6
 13 12  1  0
 14  2  2  0
 15  4  2  0
 16  6  2  0
  8 17  1  0
 18 10  2  0
 19 13  2  0
 12 20  1  0
 21 35  1  0
 22 21  1  0
 23 17  1  0
 11 24  1  0
 25  1  1  0
 26 13  1  0
 27 29  1  0
 28 30  2  0
 29 23  2  0
 30 23  1  0
 31  7  1  0
 32 10  1  0
 33 25  1  0
 34 20  1  0
 35 42  1  0
 36 24  1  0
 24 37  1  1
 38 34  1  0
 39 34  1  0
 40 32  1  0
 41 36  1  0
 42 43  1  0
 43 40  1  0
 31 33  1  0
 28 22  1  0
 22 27  2  0
  7 44  1  6
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 600.76	Molecular Weight (Monoisotopic): 600.3523	AlogP: 2.80	#Rotatable Bonds: 9
Polar Surface Area: 154.14	Molecular Species: ACID	HBA: 6	HBD: 4
#RO5 Violations: 1	HBA (Lipinski): 11	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.11	CX Basic pKa: ┄	CX LogP: 3.10	CX LogD: 0.01
Aromatic Rings: 1	Heavy Atoms: 43	QED Weighted: 0.34	Np Likeness Score: 0.51

References

1. Lundquist JT, Dix TA.. (1999) Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues., 9 (17): [PMID:10498212] [10.1016/s0960-894x(99)00420-5]
2. Chalon, P P and 8 more authors. 1996-05-20 Molecular cloning of a levocabastine-sensitive neurotensin binding site. [PMID:8647296]
3. Hughes, Francis M and 10 more authors. 2010-06-24 Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. [PMID:20481538]
4. Fanelli, Roberto R and 9 more authors. 2017-04-27 Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues. [PMID:28368584]
5. Keller, Max and 10 more authors. 2020-01-09 Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity. [PMID:31938457]
6. Chartier, Magali and 6 more authors. 2021-02-25 Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic. [PMID:33538583]

(S)-2-{(R)-2-[((3S,6S)-5,11-Dioxo-17-oxa-4,10-diaza-tricyclo[16.2.2.06,10]docosa-1(21),18(22),19-triene-3-carbonyl)-amino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source

(S)-2-{(R)-2-[((3S,6S)-5,11-Dioxo-17-oxa-4,10-diaza-tricyclo[16.2.2.0*6,10*]docosa-1(21),18(22),19-triene-3-carbonyl)-amino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source

(S)-2-{(R)-2-[((3S,6S)-5,11-Dioxo-17-oxa-4,10-diaza-tricyclo[16.2.2.06,10]docosa-1(21),18(22),19-triene-3-carbonyl)-amino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid